Orthofix Medical stock sits 41.79 percent below its yearly high with USD 399.8 million value

Published on 10/20/2026 at 20:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Orthofix Medical had USD 399.8 million in market value on October 20, 2026. Orthofix Medical stock costs EUR 8.83 on October 20, 2026.

Market facts at a glance

Orthofix Medical had a USD 399.8 million market capitalization on October 20, 2026.
Five analysts held a consensus Hold rating with a USD 14.75 average target on October 11, 2026.
Orthofix Medical stock costs EUR 8.83 at Lang & Schwarz on October 20, 2026 at 8:14 p.m. CEST.

OFIX, US68752M1080, Illustration mit AI erstellt.

Orthofix Medical (ISIN US68752M1080) had a USD 399.8 million market capitalization on October 20, 2026, while its Nasdaq-listed stock remained a small-cap medical technology name. The company develops spinal implants, biologics, limb reconstruction systems and enabling technologies for musculoskeletal care, according to its Orthofix Medical investor-relations page. Orthofix Medical was trading at EUR 8.83 at Lang & Schwarz on October 20, 2026 at 8:14 p.m. CEST.

Analysts see a higher target

MarketBeat reported on October 11, 2026 that five analysts had a consensus Hold rating for Orthofix Medical. The group included three buy ratings, one hold and one sell, with an average 12-month target of USD 14.75, according to MarketBeat. The target was above the recent USD 9.17 share price cited in that report, but the mixed rating distribution shows that the valuation case is not uniform.

Stock remains near its yearly floor

The latest structured quote put OFIX at USD 9.89 on October 20, 2026 at 2:22 p.m. ET, with a USD 8.50 to USD 16.99 52-week range and 154,030 shares traded. The current quote was USD 1.10 above the yearly low and USD 7.10 below the yearly high. These levels place the stock closer to the lower end of its annual trading band than to its high.

Quarterly losses remain relevant

Orthofix reported USD 210.93 million of revenue and a USD 0.39 adjusted loss per share for the second quarter of 2026, compared with a USD 209.28 million revenue consensus and a USD 0.40 expected loss, according to Investing.com. The same report said the company raised its full-year 2026 sales and adjusted EBITDA guidance after reimbursement and distribution developments.

What the valuation leaves open

The central contrast is between the USD 14.75 analyst target and the latest USD 9.89 Nasdaq quote. Orthofix also carried USD 873.0 million of total assets at June 30, 2026, while operating cash flow was negative USD 6.2 million in the second quarter of 2026. That combination leaves profitability and cash generation as important measures for the next reported period.

Orthofix Medical stock in euros

Orthofix Medical was trading at EUR 8.83 at Lang & Schwarz on October 20, 2026 at 8:14 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Orthofix Medical stock.